Michael Halstead - Dec 21, 2021 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
EVP and General Counsel
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Dec 21, 2021
Transactions value $
-$5,514,784
Form type
4
Date filed
12/23/2021, 06:02 PM
Previous filing
Jul 7, 2023
Next filing
Jan 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $347K +25K $13.86* 25K Dec 21, 2021 Direct
transaction ITCI Common Stock Options Exercise $1.55M +88.1K +352.58% $17.57 113K Dec 21, 2021 Direct
transaction ITCI Common Stock Options Exercise $1M +63.7K +56.31% $15.73 177K Dec 21, 2021 Direct
transaction ITCI Common Stock Sale -$1.1M -22.6K -12.79% $48.62 154K Dec 21, 2021 Direct F1, F2
transaction ITCI Common Stock Sale -$5.01M -105K -67.93% $47.84 49.5K Dec 21, 2021 Direct F1, F3
transaction ITCI Common Stock Sale -$1.71M -36.4K -73.65% $46.87 13K Dec 21, 2021 Direct F1, F4
transaction ITCI Common Stock Sale -$397K -8.69K -66.67% $45.74 4.34K Dec 21, 2021 Direct F1, F5
transaction ITCI Common Stock Sale -$195K -4.34K -100% $44.87 0 Dec 21, 2021 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -25K -100% $0.00* 0 Dec 21, 2021 Common Stock 25K $13.86 Direct F7
transaction ITCI Stock Option (right to buy) Options Exercise $0 -88.1K -100% $0.00* 0 Dec 21, 2021 Common Stock 88.1K $17.57 Direct F7
transaction ITCI Stock Option (right to buy) Options Exercise $0 -63.7K -100% $0.00* 0 Dec 21, 2021 Common Stock 63.7K $15.73 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.30 to $49.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $48.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.29 to $47.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.25 to $46.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.25 to $45.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7 All shares underlying this option have vested.